| Previous close | 8.15 |
| Open | 8.15 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 20.00 |
| Expiry date | 2024-05-31 |
| Day's range | 5.55 - 8.15 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
UPDATE 1-Pfizer offers up to $250 mln to settle Zantac cancer lawsuits, FT reports
Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
ReutersPfizer offers up to $250 million to settle Zantac cancer lawsuits, FT reports
The drugmaker was set to pay between $200 million and $250 million in the settlement, the newspaper reported, citing two people briefed on the deal. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.
Investor's Business DailyPfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Pfizer stock is now above its key moving averages after reporting better-than-expected first-quarter sales. Is PFE stock a buy now?
